- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy ; volume:19 ; number:1 ; day:4 ; month:3 ; year:2019 ; pages:1-11 ; date:12.2019
BMC cancer ; 19, Heft 1 (4.3.2019), 1-11, 12.2019
- Urheber
-
Kazlauskas, Arunas
Darinskas, Adas
Meškys, Rolandas
Tamašauskas, Arimantas
Urbonavičius, Jaunius
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-5409-7
- URN
-
urn:nbn:de:101:1-2019033002114269736579
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kazlauskas, Arunas
- Darinskas, Adas
- Meškys, Rolandas
- Tamašauskas, Arimantas
- Urbonavičius, Jaunius
- SpringerLink (Online service)
Ähnliche Objekte (12)
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy
CD95L pro-drug : a novel Swiss Army Knife in cancer therapy?
Targeted enzyme prodrug therapy for metastatic prostate cancer – a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase
Novel glycosyl prodrug of RXP03 as MMP-11 prodrug: design, synthesis and virtual screening
Nanoparticulation of Prodrug into Medicines for Cancer Therapy
Novel Prodrug Strategies for the Treatment of Tuberculosis
Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy
Glutathione‐Responsive Nanoparticles of Camptothecin Prodrug for Cancer Therapy
The cytidine deaminase under-representation reporter (CDUR) as a tool to study evolution of sequences under deaminase mutational pressure
Rational Design of Responsive Prodrug-based Nanomedicines for Antitumor Therapy
Dual-vector prodrug activator gene therapy using retroviral replicating vectors
Near-infrared light-triggered nano-prodrug for cancer gas therapy
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy
CD95L pro-drug : a novel Swiss Army Knife in cancer therapy?
Targeted enzyme prodrug therapy for metastatic prostate cancer – a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase
Novel glycosyl prodrug of RXP03 as MMP-11 prodrug: design, synthesis and virtual screening
Nanoparticulation of Prodrug into Medicines for Cancer Therapy
Novel Prodrug Strategies for the Treatment of Tuberculosis
Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy
Glutathione‐Responsive Nanoparticles of Camptothecin Prodrug for Cancer Therapy
The cytidine deaminase under-representation reporter (CDUR) as a tool to study evolution of sequences under deaminase mutational pressure
Rational Design of Responsive Prodrug-based Nanomedicines for Antitumor Therapy
Dual-vector prodrug activator gene therapy using retroviral replicating vectors
Near-infrared light-triggered nano-prodrug for cancer gas therapy
Engineering Extracellular Vesicles with the Tools of Enzyme Prodrug Therapy
CD95L pro-drug : a novel Swiss Army Knife in cancer therapy?
Targeted enzyme prodrug therapy for metastatic prostate cancer – a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase
Novel glycosyl prodrug of RXP03 as MMP-11 prodrug: design, synthesis and virtual screening
Nanoparticulation of Prodrug into Medicines for Cancer Therapy
Novel Prodrug Strategies for the Treatment of Tuberculosis
Prodrug-conjugated tumor-seeking commensals for targeted cancer therapy
Glutathione‐Responsive Nanoparticles of Camptothecin Prodrug for Cancer Therapy
The cytidine deaminase under-representation reporter (CDUR) as a tool to study evolution of sequences under deaminase mutational pressure
Rational Design of Responsive Prodrug-based Nanomedicines for Antitumor Therapy
Dual-vector prodrug activator gene therapy using retroviral replicating vectors